UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 1, 2013

Medizone International, Inc.

(Exact name of registrant as specified in its charter)

Nevada (State or other jurisdiction of incorporation) 2-93277-D (Commission File Number) 87-0412648 (IRS Employer Identification No.)

4000 Bridgeway, Suite 401, Sausalito, California 94965

(Address of principal executive offices, Zip Code)

Registrant's telephone number, including area code:(415) 331-0303

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On May 1, 2013, Medizone International, Inc., a Nevada corporation (the “Registrant”), posted a Chairman’s Shareholder Update on its corporate website (http://www.medizoneint.com/ ) containing updates on recent developments and forward-looking statements regarding the Registrant’s recently commenced distribution of its patented disinfection system known as AsepticSure®.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1  Letter from Chairman as posted on corporate website May 1, 2013.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Medizone International, Inc.
By:	/s/ Edwin G. Marshall
	Edwin G. Marshall Chief Executive Officer

Date: May 1, 2013